Skip to content
Trial Eligibility
Menu

MASH / NASH (Fatty Liver Disease) Clinical Trials Recruiting in the US

82 studies for MASH / NASH (Fatty Liver Disease) are recruiting at 1,461 US sites, according to ClinicalTrials.gov data processed .

MASH, formerly called NASH, is a form of fatty liver disease in which fat build-up in the liver is accompanied by inflammation and liver cell damage.

Your ZIP is looked up in your browser. We don't receive or store it.

Recruiting now

Top MASH / NASH (Fatty Liver Disease) studies by number of US sites

Showing 30 studies, most US recruiting sites first.
  1. A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

    NCT06528314

    • Phase 3
    • Ages 18 to 80 years
    • Sex: All
    Recruiting sites
    160 US recruiting sites
  2. A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

    NCT06215716

    • Phase 3
    • Ages 18 to 80 years
    • Sex: All
    Recruiting sites
    159 US recruiting sites
  3. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

    NCT06632444

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    155 US recruiting sites
  4. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    NCT07165028

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    137 US recruiting sites
  5. A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

    NCT06318169

    • Phase 3
    • Ages 18 to 80 years
    • Sex: All
    Recruiting sites
    136 US recruiting sites
  6. A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

    NCT06419374

    • Phase 3
    • Ages 18 to 75 years
    • Sex: All
    Recruiting sites
    131 US recruiting sites
  7. LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

    NCT06632457

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    124 US recruiting sites
  8. A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

    NCT07221227

    • Phase 3
    • Ages 18 to 75 years
    • Sex: All
    Recruiting sites
    76 US recruiting sites
  9. A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

    NCT07288138

    • Phase 2
    • Ages 18 to 75 years
    • Sex: All
    Recruiting sites
    67 US recruiting sites
  10. A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

    NCT07221188

    • Phase 3
    • Ages 18 to 75 years
    • Sex: All
    Recruiting sites
    58 US recruiting sites
  11. A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

    NCT05519475

    • Phase 2
    • Ages 18 to 75 years
    • Sex: All
    Recruiting sites
    35 US recruiting sites
  12. A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)

    NCT07491458

    • Phase 2
    • Ages 30 years and older
    • Sex: All
    Recruiting sites
    31 US recruiting sites
  13. A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

    NCT06920043

    • Phase 2
    • Ages 18 to 75 years
    • Sex: All
    Recruiting sites
    30 US recruiting sites
  14. A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

    NCT07704892

    • Phase 3
    • Ages 18 to 75 years
    • Sex: All
    Recruiting sites
    18 US recruiting sites
  15. Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

    NCT05832229

    • Phase 2
    • Ages 18 to 75 years
    • Sex: All
    Recruiting sites
    13 US recruiting sites
  16. A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

    NCT07701993

    • Phase 3
    • Ages 18 to 75 years
    • Sex: All
    Recruiting sites
    13 US recruiting sites
  17. Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH

    NCT07335601

    • Phase 2
    • Ages 18 to 75 years
    • Sex: All
    Recruiting sites
    12 US recruiting sites
  18. A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

    NCT07527910

    • Phase 2
    • Ages 18 to 75 years
    • Sex: All
    Recruiting sites
    9 US recruiting sites
  19. Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH

    NCT07795164

    • Phase 3
    • Ages 18 to 75 years
    • Sex: All
    Recruiting sites
    9 US recruiting sites
  20. Non-Invasive Quantification of Liver Health in NASH (N-QUAN)

    NCT04054310

    • Interventional
    • Ages 18 to 75 years
    • Sex: All
    Recruiting sites
    6 US recruiting sites
  21. A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

    NCT05648214

    • Phase 1/2
    • Ages 18 to 75 years
    • Sex: All
    • Accepts healthy volunteers
    Recruiting sites
    5 US recruiting sites
  22. A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV

    NCT07143968

    • Phase 2
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    5 US recruiting sites
  23. Evaluation of Non-Invasive Tests for Metabolic Liver Disease

    NCT07122700

    • Observational
    • Ages 18 to 75 years
    • Sex: All
    Recruiting sites
    4 US recruiting sites
  24. A Study of Efimosfermin Alfa in Adults With Hepatic Impairment

    NCT07358546

    • Phase 1
    • Ages 18 to 70 years
    • Sex: All
    Recruiting sites
    3 US recruiting sites
  25. Quantifying Hepatic Mitochondrial Fluxes in Humans

    NCT05305287

    • Phase 4
    • Ages 18 to 80 years
    • Sex: All
    Recruiting sites
    2 US recruiting sites
  26. Predicting Outcomes in Nonalcoholic Steatohepatitis With Advanced Fibrosis

    NCT05720663

    • Observational
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    2 US recruiting sites
  27. Endoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver Disease

    NCT05728697

    • Observational
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    2 US recruiting sites
  28. Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial

    NCT06138821

    • Interventional
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    2 US recruiting sites
  29. Digoxin In NASH (CODIN)

    NCT06588699

    • Phase 2
    • Ages 18 to 75 years
    • Sex: All
    Recruiting sites
    2 US recruiting sites
  30. Endoscopic Ultrasound Shear Wave Elastography Study

    NCT06592820

    • Observational
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    2 US recruiting sites

By city

MASH / NASH (Fatty Liver Disease) clinical trials by city

FAQ

Common questions

What is a clinical trial?
A clinical trial is a research study in people that tests a medical, surgical or behavioral intervention, such as an investigational drug or device. Observational studies are also listed: they collect information without assigning a treatment. Read how clinical trials work.
Is there compensation for joining a MASH / NASH (Fatty Liver Disease) clinical trial?
Compensation for time and travel may be available, but it varies by study and some studies offer none. The amount and schedule are reviewed by an ethics board and described in the consent form. See compensation in clinical trials.
How do I check if I'm eligible?
Each study lists age, sex and other inclusion and exclusion criteria on its ClinicalTrials.gov record. Only the study team can confirm eligibility, usually through a screening call or visit. Talk with your own doctor before joining any study.

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.